Tixagevimab And Cilgavimab

Introduction Overview

Generic Name

tixagevimab and cilgavimab

Brand Name

Evusheld

Dosage Form

intramuscular injection

Drug Class

Antiviral combinations

Pharmacokinetics

Absorption:
Evusheld is administered via intramuscular (IM) injection, typically into the gluteal muscle. Following IM administration, the absorption of the monoclonal antibodies tixagevimab and cilgavimab occurs gradually as the large protein molecules are released into the systemic circulation through the lymphatic system and capillary networks. Peak serum concentrations are typically achieved several days post-injection due to the slower absorption rate associated with IM delivery compared to intravenous routes. This absorption profile allows for prolonged systemic exposure, which is essential for sustained prophylactic effects against SARS-CoV-2 infection. Factors such as injection site blood flow, muscle mass, and individual patient variability can influence the absorption kinetics.

Distribution:
Once absorbed, tixagevimab and cilgavimab distribute primarily within the vascular and interstitial compartments, consistent with the distribution behavior of immunoglobulin G1 (IgG1) antibodies. These monoclonal antibodies exhibit limited penetration across the blood-brain barrier and sequestration in intracellular compartments. The volume of distribution is relatively low, reflecting confinement largely to plasma and extracellular fluid. Being large molecules, their tissue distribution is influenced by Fc receptor-mediated transport and binding to target spike proteins on circulating viral particles. No significant accumulation in non-target tissues has been reported. Protein binding is high, typical of IgG antibodies, with no significant displacement interactions noted.

Metabolism:
Tixagevimab and cilgavimab, as monoclonal antibodies, undergo catabolism primarily through proteolytic degradation in the reticuloendothelial system and within various tissues. These catabolic pathways hydrolyze the peptides into small peptides and amino acids, which are then recycled or eliminated via normal metabolic pathways. Unlike small molecule drugs, they are not subjected to hepatic cytochrome P450 enzyme metabolism. Their long half-lives are partly due to neonatal Fc receptor (FcRn)-mediated recycling, which protects them from lysosomal degradation, thereby prolonging systemic presence.

Elimination:
The clearance of tixagevimab and cilgavimab occurs by nonspecific catabolic processes typical of IgG antibodies rather than renal or hepatic routes. The elimination half-life for both monoclonal antibodies is estimated to be approximately 3 weeks to 4 weeks, which supports their dosing interval every six months for pre-exposure prophylaxis. Clearance kinetics are affected minimally by body weight, age, or mild organ impairment. The long half-life enables sustained neutralization capacity against SARS-CoV-2 spike protein. There is no evidence of active excretion or metabolism through conventional pathways for small molecules, reflecting their protein-based nature.

Dosage Forms

Available Dosage Forms:
Evusheld is provided as two distinct vials, each containing one of the active monoclonal antibodies: tixagevimab and cilgavimab. Each vial is intended for intramuscular injection. The drug comes in single-dose injectable vials containing a fixed concentration of each antibody, with no oral or intravenous formulations available.

Dosages for Adults and Adolescents:
The dosing regimen authorized under the Emergency Use Authorization (now revoked) was initially 300 mg of tixagevimab and 300 mg of cilgavimab administered as two separate consecutive intramuscular injections at different sites. This dosing schedule applied to adults and adolescents aged 12 years and older weighing at least 40 kg (88 lbs). For individuals who originally received 150 mg of each antibody, a repeat dose of 300 mg of each was recommended after three months, followed by doses every six months. Repeat dosing was timed relative to the last administration to maintain protective serum levels.

Specific Patient Populations:
Evusheld was intended primarily for individuals with moderate to severe immunocompromise or those for whom COVID-19 vaccination was contraindicated due to severe adverse reactions. In this population, dosing was consistent with that in the general approved age and weight groups, with the necessity of repeat administration every six months. No specific dose adjustments were needed for renal or hepatic impairment as metabolism and elimination are not primarily organ-dependent. Pediatric use below 12 years or under 40 kg was not authorized. Geriatric dosing followed the standard adult dosing without modification.

Detailed Dosage Form Values:
- Intramuscular injection vial containing tixagevimab (dose per vial: either 150 mg or 300 mg depending on administration schedule)
- Intramuscular injection vial containing cilgavimab (dose per vial: either 150 mg or 300 mg depending on administration schedule)
Each administration includes two separate injections sequentially given at different sites to complete the 1:1 antibody combination dosing for prophylaxis.

Mechanism Of Action

Evusheld is a combination of two human IgG1κ monoclonal antibodies, tixagevimab and cilgavimab, specifically engineered to target distinct epitopes on the SARS-CoV-2 spike glycoprotein. Both antibodies bind with high affinity to the receptor-binding domain (RBD) of the spike protein, which the virus utilizes to attach to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells. By binding to separate, non-overlapping sites on the spike protein, the antibodies function synergistically to prevent viral attachment, thereby blocking cell entry and subsequent infection.

At the molecular level, the binding of Evusheld’s monoclonal antibodies sterically hinders the interaction between the spike protein and ACE2 receptor. This action effectively neutralizes the virus, preventing conformational changes necessary for membrane fusion and viral RNA entry into host cells. The dual antibody approach reduces the likelihood of viral escape mutations compromising treatment efficacy, as simultaneous mutations at both epitopes are less probable, conferring a broader neutralizing capacity against SARS-CoV-2 variants.

Cellularly, upon administration, these antibodies circulate systemically and remain in extracellular fluids, where they can encounter free virus particles. They facilitate neutralization prior to viral attachment to and infection of target epithelial cells in the respiratory tract. Their IgG1 backbone also engages immune effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis, potentially aiding in clearance of infected cells or viral particles, although the primary function is viral neutralization.

Clinically, this mechanism enables Evusheld to be used as pre-exposure prophylaxis, providing immediate passive immunity to individuals who are either immunocompromised or unable to mount an adequate vaccine response. Unlike active vaccines, Evusheld does not elicit endogenous antibody production but supplies exogenous neutralizing antibodies that provide protection until catabolized. Compared to other antiviral agents, such as small molecule inhibitors targeting viral replication, Evusheld acts extracellularly to block viral entry, offering a complementary mechanism of action. Research studies and clinical trials demonstrated that the combination effectively reduces the incidence of symptomatic COVID-19 infection in high-risk populations when administered prophylactically.

Pharmacological Actions

Neutralization of SARS-CoV-2 virus by binding to spike protein receptor-binding domain.
Prevention of viral attachment to host ACE2 receptors, blocking viral entry into cells.
Provision of passive immunization via administration of exogenous monoclonal antibodies.
Dual antibody binding to non-overlapping epitopes reduces viral escape through mutations.
Engagement of immune effector functions such as antibody-dependent cellular cytotoxicity.
Specific targeting of SARS-CoV-2 variants, including several concerning strains present at time of authorization.
Long systemic half-life allowing sustained protective antibody levels over months.
Intramuscular administration facilitating outpatient use and ease of repeated prophylaxis dosing.
Production via recombinant DNA technology ensuring high purity and humanized antibody structure minimizing immunogenicity.
Does not interfere with active COVID-19 vaccination but may temporarily reduce vaccine-induced immunity if administered closely.
Lack of systemic metabolism via cytochrome P450 enzymes prevents common small molecule drug interactions.
Designed to provide protection in populations unable to respond effectively to vaccination.
Administered as two separate monoclonal antibodies to maximize neutralizing breadth against spike protein variants.
Not authorized for treatment or post-exposure prophylaxis, specifically indicated for pre-exposure prophylaxis.
Potential for rare immunologic adverse events including hypersensitivity due to protein nature.

Therapeutic Or Clinical Uses

Pre-exposure prophylaxis for COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg.
Prevention of SARS-CoV-2 infection in individuals with moderate-to-severe immunocompromise.
Use in patients with history of severe adverse reactions to COVID-19 vaccines or contraindications to vaccination.
Passive immunization alternative for patients unlikely to mount adequate immune response to vaccines.
Prophylactic protection for patients undergoing immunosuppressive therapies such as chemotherapy or organ transplantation.
Protection for patients with primary immunodeficiencies like DiGeorge syndrome or Wiskott-Aldrich syndrome.
Preventive agent in patients with advanced or untreated HIV infection with poor immune reconstitution.
Used in clinical scenarios where vaccination is either inadvisable or has been ineffective.
Recommended repeat dosing every six months for continued protection against COVID-19 infection.
Supportive measure complementing public health vaccination efforts in high-risk populations.
Not authorized for treatment of active COVID-19 infection or for post-exposure prophylaxis after contact with SARS-CoV-2.
Emergency Use Authorization prior to withdrawal allowed limited access for pre-exposure prophylaxis during pandemic period.
Facilitates reduction in COVID-19 infection rates among high-risk groups in clinical trial settings.
Part of comprehensive management strategy for immunocompromised patients during pandemic.
Utilized in specialized care environments like transplant clinics and oncology units for prophylaxis.

Side Or Adverse Effects

Hypersensitivity reactions including anaphylaxis during or after administration.
Local injection site reactions such as pain, bruising, swelling, soreness, or bleeding.
Rare serious cardiac adverse events, particularly in patients with pre-existing cardiovascular risk factors.
Symptoms of cardiac events may include chest pain, shortness of breath, fatigue, or limb swelling.
Signs of allergic reactions include rash, hives, itching, wheezing, and facial or throat swelling.
Potential for lightheadedness, nausea, vomiting, chills, muscle aches, or flushing post-injection.
Possibility of immunologic reactions due to polysorbate 80 excipient, related to polyethylene glycol sensitivity.
No widespread systemic adverse effects documented due to limited population exposure.
Injection site infections are possible but rare with proper sterile techniques.
Adverse effect profile remains under continuing post-marketing surveillance.
Fatigue and weakness reported in some patients following administration.
No known hepatotoxic or nephrotoxic effects identified to date.
No significant drug-related hematologic toxicity observed.
Potential for unknown or rare adverse effects due to limited study population and emergency use status.
Patients monitored for at least one hour post-injection for immediate hypersensitivity reactions.

Precautions

Use cautiously in patients with history of severe allergic reactions to monoclonal antibodies or components of the formulation.
Inform healthcare provider of any prior severe allergic reactions to COVID-19 vaccines or vaccine components such as polyethylene glycol.
Monitor patients closely for signs of hypersensitivity during and after administration.
Patients with bleeding disorders or thrombocytopenia should be assessed carefully due to intramuscular injection risks.
Discuss cardiac history thoroughly, especially in individuals with prior myocardial infarction or stroke.
Evaluate risk-benefit carefully in pregnant or breastfeeding women given limited safety data.
Delay administration of Evusheld for at least two weeks after COVID-19 vaccination to avoid interference with vaccine response.
Ensure correct intramuscular injection technique to minimize local injection site complications.
Repeated dosing advised only when ongoing protection is clinically indicated; maintain adherence to dosing schedule.
Patients advised to report any new symptoms related to cardiac or allergic events promptly.
Adequate assessment recommended prior to administration in immunocompromised patients with fluctuating clinical status.
Avoid use in individuals with current SARS-CoV-2 infection or recent close contact with infected persons.
Storage conditions must be strictly maintained to preserve drug efficacy and safety.
Healthcare providers should be prepared to manage acute allergic reactions including anaphylaxis.
Vaccination remains the primary preventive strategy; Evusheld does not replace COVID-19 vaccination where recommended.

Warnings

Evusheld was authorized only under Emergency Use Authorization, which has now been revoked; it is no longer authorized for use in the U.S.
Risk of severe allergic reactions exists, including anaphylaxis requiring immediate medical intervention.
Rare but serious cardiac events noted in clinical trials among patients with underlying cardiac risk factors.
Not recommended for treatment of active COVID-19 infection or post-exposure prophylaxis.
Potential for reduced immune response to COVID-19 vaccines if given within two weeks.
Use may be associated with unknown risks given limited clinical trial and post-marketing exposure.
Injection site reactions may occur and should be monitored carefully.
Drug is not intended to replace vaccination in persons for whom vaccination is recommended.
Expired product should not be used as all lot supplies are no longer authorized or available.
Careful patient selection is critical to avoid inappropriate use outside approved indications.
Continuous monitoring for adverse cardiac events advised, especially in populations with cardiovascular disease.
Not established to be safe or effective in pediatric patients under 12 years or body weight below 40 kg.
Hypersensitivity risk elevated in patients with allergy to polysorbate 80 or related excipients.
Healthcare providers must be trained in recognition and management of infusion-related reactions.
Storage warnings: do not freeze or shake; product must be protected from light and refrigerated.

Contraindication

Known severe allergic reaction (anaphylaxis) to tixagevimab or cilgavimab.
Allergy to any component of the formulation, including polysorbate 80 or other inactive ingredients.
Current active SARS-CoV-2 infection or symptomatic COVID-19 disease.
Use for treatment of COVID-19 or post-exposure prophylaxis following known exposure is contraindicated.
Individuals younger than 12 years or weighing less than 40 kilograms due to lack of safety data.
Patients with hypersensitivity to other monoclonal antibodies with similar structural components.
Use of expired product or product not stored under recommended conditions.
Concurrent participation in other interventional COVID-19 treatment trials without coordination.
Patients who are unwilling or unable to comply with intramuscular injection protocol.
Contraindicated in scenarios where clinical benefit-risk assessment does not favor administration.
Known hypersensitivity to polyethylene glycol-containing compounds should be cautiously avoided.
Severe uncontrolled cardiac disease may preclude use given reported cardiac events.
Individuals with bleeding disorders should avoid IM injections unless benefits outweigh risks.
Hypersensitivity to recombinant Chinese hamster ovary (CHO) cell products (the production system) is a precaution and contraindication if documented.
Presence of acute severe illness until stabilization may contraindicate administration.

Drug Interactions

No significant drug-drug interactions have been reported due to lack of cytochrome P450 metabolism of Evusheld antibodies.
Potential interaction with immunosuppressive agents that may alter the pharmacodynamics or effectiveness of antibodies.
Concurrent use with anticoagulants or antiplatelet drugs requires caution due to risk of injection site bleeding.
Polysorbate 80 excipient may cause hypersensitivity reactions in patients also exposed to PEG-containing vaccines or drugs.
Minimal potential for interference with other monoclonal antibody therapeutics; clinical monitoring recommended.
No known significant interactions with common over-the-counter medications, herbal supplements, or vitamins.
Possible reduced immune response if administered too closely after COVID-19 vaccination.
No interaction expected with antiviral small-molecule agents used for COVID-19 treatment due to differing mechanisms.
No evidence of interference with hormonal therapies or chronic disease medications.
Monitoring advised when co-administered with biological immune-modulating agents to assess additive immunosuppressive effects.
No interaction reported with commonly used cardiovascular, metabolic, or psychiatric medications.
Avoid co-administration with other investigational monoclonal antibodies unless under clinical supervision.
Use with caution when combined with therapies that predispose to hypersensitivity reactions.
No dose adjustment needed when administered with concomitant medications based on current data.
Patients should inform healthcare providers of all medications as precaution despite low documented interaction potential.

Preparations Of The Drug

Evusheld is supplied as two single-dose glass vials, each vial containing one active ingredient: tixagevimab or cilgavimab.
Each vial contains a sterile, preservative-free solution for intramuscular injection formulated at specific concentrations for dosing flexibility.
Inactive ingredients in each vial include L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, sucrose, and water for injection.
Vials must be stored refrigerated at 2°C to 8°C (36°F to 46°F) and protected from light by retaining original carton packaging.
Do not freeze or shake the vials as this may lead to denaturation or loss of drug efficacy.
Unused portions of the vial must be discarded; no remainder from previously opened vials should be used.
Vials are designed for single patient use, with administration of two separate consecutive injections — one from each vial.
Supplied under strict Good Manufacturing Practice (GMP) conditions using recombinant DNA technology in Chinese hamster ovary (CHO) cells.
The solution is clear to slightly opalescent, colorless to pale yellow, and free from visible particles.
Packaging includes detailed prescribing and handling instructions to ensure proper administration and storage.
Material safety information advises handling as a biological agent with appropriate precautions for healthcare personnel.
Shelf life is determined based on controlled storage conditions, with specific expiry dating communicated on packaging.
Supplied in cartons containing one vial of each monoclonal antibody to facilitate immediate sequential dosing.
No preservatives are present in the preparation, necessitating aseptic technique during handling.
The product is not intended for intravenous, subcutaneous, or oral administration.